PROS1 and benign prostatic hyperplasia: A prospective cohort study involving 91 patients with COVID-19 diagnosed with BPH reported that the prostate-specific antigen (PSA) level of the patients during their COVID-19 infection period was significantly higher compared to the pre-COVID-19 (p < 0.001) and post-COVID-19 periods (p < 0.001).